NCT06782646View on ClinicalTrials.gov

Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Hyperlipidemia
Interventions
DRUG

Berberine

Participants will take purified berberine (500 mg orally twice a day) for 12 weeks.

DRUG

Placebo

Participants will take placebo tablets, a look-alike substance that contains no drug, (500 mg orally twice a day) for 12 weeks.

Trial Locations (1)

Unknown

School of Public Health, The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER